Due to its unique properties, Lp(a) can vary in size and has no single, defined molecular weight. For this reason, there is a consensus in the scientific community that Lp(a) levels should be measured ...

Approximately one in five people worldwide has elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke. 1 The Roche Diagnostics ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...

Among patients with stable chest pain and suspected CAD, elevated levels of lipoprotein(a) seem to indicate a greater likelihood of finding coronary stenosis on coronary computed tomography ...

Two therapeutic approaches to Lp(a) lowering are currently under investigation. Injectable RNA-based therapies that prevent translation of LPA messenger RNA may block the production of ApoA used ...

Most of these new drugs work by silencing the instructions from the LPA gene so a protein that is a key part of Lp(a) cholesterol isn’t produced. Muvalaplin works differently. It interferes ...

VERVE-301 uses a novel, in vivo gene editing approach designed to permanently turn off the LPA gene in the liver to reduce blood lipoprotein(a) [Lp(a)] levels. Lp(a) is a genetically validated ...

LPA, a gene associated with lipoprotein(a), emerged as a novel risk factor for AMD. This is the first study to link LPA to AMD, suggesting a role in drusen formation. Reliance on retrospective ...

This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five ...